Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker

British Journal of Haematology

Volumn 125, Issue 6, 2004, Pages 729-742

  McElwaine, Suzanne ^a   Mulligan, Claire ^a   Groet, Jürgen ^a   Spinelli, Monica ^b   Rinaldi, Andrea ^b   Denyer, Gareth ^c   Mensah, Afua ^a   Cavani, Simona ^d   Baldo, Chiara ^d   Dagna Bricarelli, Franca ^d   Hann, Ian ^e   Basso, Giuseppe ^b   Cotter, Finbarr E ^a   Nizetic, Dean ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF SYDNEY   (Australia)

^d GALLIERA HOSPITAL   (Italy)

^e HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Acute megakaryoblastic leukaemia (M7); Down's syndrome; Microarray; Transient myeloproliferative disorder

Indexed keywords

BIOLOGICAL MARKER; PRAME ANTIGEN; RNA; TRANSCRIPTION FACTOR GATA 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN SYNDROME; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; GENE EXPRESSION; HUMAN; LEUKEMOGENESIS; MALE; MYCN ONCOGENE; MYELOPROLIFERATIVE DISORDER; NEWBORN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRESCHOOL CHILD; PRIORITY JOURNAL; STUDENT T TEST;

ACUTE DISEASE; ANTIGENS, NEOPLASM; CELL CYCLE PROTEINS; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DIAGNOSIS, DIFFERENTIAL; DOWN SYNDROME; FEMALE; GENETIC MARKERS; HUMANS; INFANT, NEWBORN; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MALE; MYELOPROLIFERATIVE DISORDERS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS; REMISSION, SPONTANEOUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 3042636440     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04982.x     Document Type: Article

References (60)

1. Abe, K., Kajii, T. & Niikawa, N. (1989) Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative syndrome. Human Genetics, 82, 313-316.
2. Ahmed, M., Sternberg, A., Hall, G., Thomas, A., Smith, O., O'Marcaigh, A., Wynn, R., Stevens, R., Addison, M., King, D., Stewart, B., Gibson, B., Roberts, I. & Vyas, P. (2003) Natural history of GATA1 mutations in Down Syndrome. Blood, 103, 2480-2489.
3. Al-Kasim, F., Doyle, J.J., Massey, G.V., Weinstein, H.J. & Zipursky, A. (2002) Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. Journal of Pediatric Hematology/Oncology, 24, 9-13.
4. Arceci, R.J. (2002) Down syndrome, transient myeloproliferative syndrome, and leukemia: bridging development and neoplasia. Journal of Pediatric Hematology/Oncology, 24, 1.
5. Blackwood, E.M. & Eisenman, R.N. (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science, 251, 1211-1217.
6. Bordow, S.B., Norris, M.D., Haber, P.S., Marshall, G.M. & Haber, M. (1998) Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. Journal of Clinical Oncology, 16, 3286-3294.
7. Cantor, A.B. & Orkin, S.H. (2002) Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene, 21, 3368-3376.
8. Cavani, S., Perfumo, C., Argusti, A., Pierluigi, M., Perroni, L., Schmiegelow, K., Petersen, M.B., Cotter, F.E., Strigini, P., Dagna-Bricarelli, F. & Nizetic, D. (1998) Cytogenetic and molecular study of 32 Down syndrome families: potential leukaemia predisposing role of the most proximal segment of chromosome 21q. British Journal of Haematology, 103, 213-216.
9. Chen, Y.-Y., Stachura, D., Letting, D., Weiss, M. & Blobel, G. (2003) Direct repression of c-MYC by GATA-1: coordination of differentiation and cell cycle arrest. Blood, 102, 60a.
10. Douglas, N.C., Jacobs, H., Bothwell, A.L. & Hayday, A.C. (2001) Defining the specific physiological requirements for c-MYC in T cell development. Natural Immunology, 2, 307-315.
11. Elagib, K.E., Racke, F.K., Mogass, M., Khetawat, R., Delehanty, L.L. & Goldfarb, A.N. (2003) RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood, 101, 4333-4341.
12. Finnegan, M.C., Hammond, D.W., Hancock, B.W. & Goyns, M.H. (1995) Activation of MYCN in a case of non-Hodgkin's lymphoma. Leukemia and Lymphoma, 18, 511-514.
13. Freson, K., Devriendt, K., Matthijs, G., Van Hoof, A., De Vos, R., Thys, C., Minner, K., Hoylaerts, M.F., Vermylen, J. & Van Geet, C. (2001) Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood, 98, 85-92.
14. Fulda, S., Lutz, W., Schwab, M. & Debatin, K.M. (1999) MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene, 18, 1479-1486.
15. Gamis, A.S. & Hilden, J.M. (2002) Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? Journal of Pediatric Hematology/Oncology, 24, 2-5.
16. Greiner, J., Ringhoffer, M., Simikopinko, O., Szmaragowska, A., Huebsch, S., Maurer, U., Bergmann, L. & Schmitt, M. (2000) Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Experimental Hematology, 28, 1413-1422.
17. Groet, J., McElwaine, S., Spinelli, M., Rinaldi, A., Burtscher, I., Mulligan, C., Mensah, A., Cavani, S., Dagna-Bricarelli, F., Basso, G., Cotter, F.E. & Nizetic, D. (2003) Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet, 361, 1617-1620.
18. Hattori, M., Fujiyama, A., Taylor, T.D., Watanabe, H., Yada, T., Park, H.S., Toyoda, A., Ishii, K., Totoki, Y., Choi, D.K., Groner, Y., Soeda, E., Ohki, M., Takagi, T., Sakaki, Y., Taudien, S., Blechschmidt, K., Polley, A., Menzel, U., Delabar, J., Kumpf, K., Lehmann, R., Patterson, D., Reichwald, K., Rump, A., Schillhabel, M., Schudy, A., Zimmermann, W., Rosenthal, A., Kudoh, J., Schibuya, K., Kawasaki, K., Asakawa, S., Shintani, A., Sasaki, T., Nagamine, K., Mitsuyama, S., Antonarakis, S.E., Minoshima, S., Shimizu, N., Nordsiek, G., Hornischer, K., Brant, P., Scharfe, M., Schon, O., Desario, A., Reichelt, J., Kauer, G., Blocker, H., Ramser, J., Beck, A., Klages, S., Hennig, S., Riesselmann, L., Dagand, E., Haaf, T., Wehrmeyer, S., Borzym, K., Gardiner, K., Nizetic, D., Francis, F., Lehrach, H., Reinhardt, R. & Yaspo, M.L. (2000) The DNA sequence of human chromosome 21. Nature, 405, 311-319.
19. Hitzler, J.K., Cheung, J., Li, Y., Scherer, S.W. & Zipursky, A. (2003) GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 101, 4301-4304.
20. Hogarty, M.D. (2003) The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Letters, 197, 173-179.
21. Homans, A.C., Verissimo, A.M. & Vlacha, V. (1993) Transient abnormal myelopoiesis of infancy associated with trisomy 21. American Journal of Pediatric Hematology and Oncology, 15, 392-399.
22. Ikeda, H., Lethe, B., Lehmann, F., van Baren, N., Baurain, J.F., de Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T. & Coulie, P.G. (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity, 6, 199-208.
23. Juretic, A., Spagnoli, G.C., Schultz-Thater, E. & Sarcevic, B. (2003) Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncology, 4, 104-109.
24. Karandikar, N.J., Aquino, D.B., McKenna, R.W. & Kroft, S.H. (2001) Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis. American Journal of Clinical Pathology, 116, 204-210.
25. Kempski, H.M., Chessells, J.M. & Reeves, B.R. (1997) Deletions of chromosome 21 restricted to the leukemic cells of children with Down syndrome and leukemia. Leukemia, 11, 1973-1977.
26. Levanon, D., Bernstein, Y., Negreanu, V., Ghozi, M.C., Bar-Am, I., Aloya, R., Goldenberg, D., Lotem, J. & Groner, Y. (1996) A large variety of alternatively spliced and differentially expressed mRNAs are encoded by the human acute myeloid leukemia gene AML1. DNA and Cell Biology, 15, 175-185.
27. Lu, G., Altman, A.J. & Benn, P.A. (1993) Review of the cytogenetic changes in acute megakaryoblastic leukemia: one disease or several? Cancer Genetics and Cytogenetics, 67, 81-89.
28. Lutz, W., Fulda, S., Jeremias, I., Debatin, K.M. & Schwab, M. (1998) MycN and IFN-gamma cooperate in apoptosis of human neuroblastoma cells. Oncogene, 17, 339-346.
29. Malynn, B.A., de Alboran, I.M., O'Hagan, R.C., Bronson, R., Davidson, L., DePinho, R.A. & Alt, F.W. (2000) N-myc can functionally replace c-MYC in murine development, cellular growth, and differentiation. Genes and Development, 14, 1390-1399.
30. Matsushita, M., Yamazaki, R., Ikeda, H. & Kawakami, Y. (2003) Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies. Leukemia and Lymphoma, 44, 439-444.
31. Mehaffey, M.G., Newton, A.L., Gandhi, M.J., Crossley, M. & Drachman, J.G. (2001) X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood, 98, 2681-2688.
32. Mulligan, C., Rochford, J., Denyer, G., Stephens, R., Yeo, G., Freeman, T., Siddle, K. & O'Rahilly, S. (2002) Microarray analysis of insulin and insulin-like growth factor-1 (IGF-1) receptor signaling reveals the selective up-regulation of the mitogen heparin-binding EGF-like growth factor by IGF-1. Journal of Biological Chemistry, 277, 42480-42487.
33. Mundschau, G., Gurbuxani, S., Gamis, A.S., Greene, M.E., Arceci, R.J. & Crispino, J.D. (2003) Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood, 101, 4298-4300.
34. Nichols, K.E., Crispino, J.D., Poncz, M., White, J.G., Orkin, S.H., Maris, J.M. & Weiss, M.J. (2000) Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nature Genetics, 24, 266-270.
35. Niikawa, N., Deng, H.X., Abe, K., Harada, N., Okada, T., Tsuchiya, H., Akaboshi, I., Matsuda, I., Fukushima, Y., Kaneko, Y., Kuwano, A. & Kajii, T. (1991) Possible mapping of the gene for transient myeloproliferative syndrome at 21q11.2. Human Genetics, 87, 561-566.
36. Orkin, S.H. (2000) Diversification of haematopoietic stem cells to specific lineages. Natural Review of Genetics, 1, 57-64.
37. Oue, T., Fukuzawa, M., Kusafuka, T., Kohmoto, Y., Imura, K., Nagahara, S. & Okada, A. (1996) In situ detection of DNA fragmentation and expression of bcl-2 in human neuroblastoma: relation to apoptosis and spontaneous regression. Journal of Pediatric Surgery, 31, 251-257.
38. Pritchard, J. & Hickman, J.A. (1994) Why does stage 4s neuroblastoma regress spontaneously? Lancet, 344, 869-870.
39. Proto-Siqueira, R., Falcao, R.P., de Souza, C.A., Ismael, S.J. & Zago, M.A. (2003) The expression of PRAME in chronic lymphoproliferative disorders. Leukemia Research, 27, 393-396.
40. Rainis, L., Bercovich, D., Strehl, S., Teigler-Schlegel, A., Stark, B., Trka, J., Amariglio, N., Biondi, A., Muler, I., Rechavi, G., Kempski, H., Haas, O.A. & Izraeli, S. (2003) Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood, 102, 981-986.
41. Rylski, M., Welch, J.J., Chen, Y.Y., Letting, D.L., Diehl, J.A., Chodosh, L.A., Blobel, G.A. & Weiss, M.J. (2003) GATA-1-mediated proliferation arrest during erythroid maturation. Molecular and Cellular Biology, 23, 5031-5042.
42. Sarcevic, B., Spagnoli, G.G., Terracciano, L., Schultz-Thater, E., Heberer, M., Gamulin, M., Krajina, Z., Oresic, T., Separovic, R. & Juretic, A. (2003) Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology, 64, 443-449.
43. Sato, T., Fuse, A., Eguchi, M., Hayashi, Y., Ryo, R., Adachi, M., Kishimoto, Y., Teramura, M., Mizoguchi, H., Shima, Y., Komori, I., Sunami, S., Okimoto, Y. & Nakajima, H. (1989) Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia. British Journal of Haematology, 72, 184-190.
44. Shen, J.J., Williams, B.J., Zipursky, A., Doyle, J., Sherman, S.L., Jacobs, P.A., Shugar, A.L., Soukup, S.W. & Hassold, T.J. (1995) Cytogenetic and molecular studies of Down syndrome individuals with leukemia. American Journal of Human Genetics, 56, 915-925.
45. Shimada, A., Maruyama, K., Shitara, T., Kato, M., Cho, K., Kobayashi, T., Fujiu, T., Tsuchida, Y., Nishida, A., Hayashi, Y., Minakami, H., Kozawa, K. & Kimura, H. (2004) Proinflammatory cytokinemia associated with transient myeloproliferative disorder in Down syndrome. Biology of the Neonate, 85, 167-172.
46. Shimizu, R., Takahashi, S., Ohneda, K., Engel, J.D. & Yamamoto, M. (2001) In vivo requirements for GATA-1 functional domains during primitive and definitive erythropoiesis. EMBO Journal, 20, 5250-5260.
47. Shivdasani, R.A., Fujiwara, Y., McDevitt, M.A. & Orkin, S.H. (1997) A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO Journal, 16, 3965-3973.
48. Speck, N.A. & Gilliland, D.G. (2002) Core-binding factors in haematopoiesis and leukaemia. Natural Review of Cancer, 2, 502-513.
49. Steinbach, D., Viehmann, S., Zintl, F. & Gruhn, B. (2002) PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 138, 89-91.
50. Taub, J.W. & Ravindranath, Y. (2002) Down syndrome and the transient myeloproliferative disorder: why is it transient? Journal of Pediatric Hematology/Oncology, 24, 6-8.
51. Tsai, S.F., Martin, D.I., Zon, L.I., D'Andrea, A.D., Wong, G.G. & Orkin, S.H. (1989) Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature, 339, 446-451.
52. Van Dongen, J. & Adriaansen, H. (1996) Immunobiology of Leukemia. In: Leukemia (ed. by E. Henderson, T.A. Lister & M. Greaves), pp. 83-130. WB Saunders Company, Philadelphia.
53. Van Trappen, P.O., Gyselman, V.G., Lowe, D.G., Ryan, A., Oram, D.H., Bosze, P., Weekes, A.R., Shepherd, J.H., Dorudi, S., Bustin, S.A. & Jacobs, I.J. (2001) Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet, 357, 15-20.
54. Wechsler, J., Greene, M., McDevitt, M.A., Anastasi, J., Karp, J.E., Le Beau, M.M. & Crispino, J.D. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics, 32, 148-152.
55. Xu, G., Nagano, M., Kanezaki, R., Toki, T., Hayashi, Y., Taketani, T., Taki, T., Mitui, T., Koike, K., Kato, K., Imaizumi, M., Sekine, I., Ikeda, Y., Hanada, R., Sako, M., Kudo, K., Kojima, S., Ohneda, O., Yamamoto, M. & Ito, E. (2003) Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood, 102, 2960-2968.
56. Yagi, T., Morimoto, A., Eguchi, M., Hibi, S., Sako, M., Ishii, E., Mizutani, S., Imashuku, S., Ohki, M. & Ichikawa, H. (2003) Identification of a gene expression signature associated with pediatric AML prognosis. Blood, 102, 1849-1856.
57. Yumura-Yagi, K., Hara, J., Kurahashi, H., Nishiura, T., Kaneyama, Y., Osugi, Y., Sakata, N., Inoue, M., Tawa, A., Okada, S. & Kawa-Ha, K. (1992) Mixed phenotype of blasts in acute megakaryocytic leukaemia and transient abnormal myelopoiesis in Down's syndrome. British Journal of Haematology, 81, 520-525.
58. Zipursky, A., Poon, A. & Doyle, J. (1992) Leukemia in Down syndrome: a review. Pediatric Hematology and Oncology, 9, 139-149.
59. Zipursky, A., Thorner, P., De Harven, E., Christensen, H. & Doyle, J. (1994) Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leukemia Research, 18, 163-171.
60. Zipursky, A., Christensen, H. & De Harven, E. (1995) Ultrastructural studies of the megakaryoblastic leukemias of Down syndrome. Leukemia and Lymphoma, 18, 341-347.